Superscan: Superiority of xSPECT/CT over OSEM SPECT/CT in bone scans of prostate cancer patients.
Publication date: Available online 28 May 2020Source: Radiation Physics and ChemistryAuthor(s): Chen Ew-Jun, Tan Teik Hin, Chew Ming Tsuey
Conclusion: The high accumulation of activity in the tumor and fast clearance from background organs was a common favorable characteristic of PSMA radioligands modified with ibuprofen as albumin-binding entity. 177Lu-Ibu-DAB-PSMA emerged as the most promising candidate; hence, more detailed preclinical investigations with this radioligand are warranted in view of a clinical translation.
Conclusion: This work demonstrates a means for efficient dose estimation in 177Lu-PSMA-617 therapy. By providing methods to simplify and potentially automate radiation dosimetry, we hope to accelerate the understanding of radiobiology and development of dose–response models in this unique therapeutic context.
AbstractMetabolic bone volume (MBV), standardized uptake value (SUV), and total bone uptake (TBU) are new imaging biomarkers for quantitative bone single-photon emission computed tomography/computed tomography. The purpose of this study was to validate the quantitative accuracy and utility of MBV, SUVmean, and TBU for the assessment of bone metastases in prostate cancer. We used a bone-specific phantom with four hot spheres (φ = 13, 17, 22, 28 mm) filled with different Tc-99 m activities to simulate uptake ratios of 3 and 7, corresponding to normal and metastatic values. We calculated the error ...
Conclusions: Our preliminary results demonstrate the potential of artificial intelligence to estimate voxel-wise post-therapy dosimetry both qualitatively and quantitatively. This may provide a practical solution to improve the dosimetry-guided treatment planning for RLT.
Conclusions: We demonstrated the feasibility of estimating radiation doses in kidneys using quantitative 177Lu-SPECT/CT for CTT1403 therapy. The absorbed dose in kidneys in the first 6 subjects was well below the threshold of 23 Gy, considered the dose limiting exposure level[SY1] [BL2] . The elimination phase half-life of CTT1403 showed prolonged retention in blood plasma for this small molecule peptidomimetic, confirming enhanced circulation time imparted by the albumin binding component. Acknowledgements: The study was supported by the National Institutes of Health under grant R44CA239461, and Cancer Targeted Technology, LLC.
1273Background: Ra-223-dichloride treatment of castration-resistant prostatic cancer has an alpha radiation-induced radiotherapeutic effect on bone metastases and prolongs the prognosis, but the mechanism by which the prognosis is prolonged is not well understood.Objectives: The purpose of this study was to observe the changes in bone accumulation using bone scintigraphy during Ra-223-dichloride therapy with a precise single-photon emission computed tomography (CT)/CT (SPECT/CT) device.Subjects and Methods: The subjects were 28 patients with Ra-223-dichloride therapy for castration-resistant prostate cancer bone metastases...
107Introduction: Robust scatter correction is necessary for accurate clinical PET quantification, particularly for challenging tracers such as gallium-68-labeled prostate-specific membrane antigen (68Ga-PSMA) which are characterized by high uptake throughout the urinary system. Halo artifact associated with overcorrection of scatter fields in the vicinity of the urinary system organs - notably the kidneys, ureters, and bladder - has been observed and is recognized as an obstacle for the clinical acceptance of 68Ga-PSMA PET [1, 2]. Recent techniques for scatter subtraction based on a Poisson maximum likelihood-based solutio...
Conclusions: In conclusion SPECT-CT imaging with 99mTc-PSMA could be applied in patients with prostate cancer for the diagnosis of recurrent disease in order to determine personalized treatment for each individual patient. Specific uptake of this tracer, depicted by SPECT-CT images has clinical importance of identifying and assessment PSMA expression before consideration of Radio Ligand Therapy (RLT) with 177Lu-PSMA. SPECT-CT imaging with 99mTc-PSMA is promising and reliable nuclear medicine approach to monitor therapeutic effect after treatment - to detect progressive/active lesions or to report full/ partial response.
Conclusions[99mTc]Tc-PSMA-I&S-SPECT/CT was useful in PSMA-targeted imaging of PCa at various clinical stages. At low PSA levels ( 4 ng/ml) [99mTc]Tc-PSMA-I&S-SPECT/CT provides high detection rates in BCR. [99mTc]Tc-PSMA-I&S-SPECT/CT can also be used for primary staging and for restaging of advanced recurrent PCa. However, further studies are needed to assess the clinical value in these indications.
CONCLUSION: 177Lu-PSMA SPECT scan can help detecting metastatic lesions in more than one third of patients with biochemical recurrence and negative conventional investigations, when 68Ga- PSMA PET is not available. PMID: 32281092 [PubMed - as supplied by publisher]